Naturally occurring autoantibodies against β-Amyloid
- PMID: 22903668
- DOI: 10.1007/978-1-4614-3461-0_7
Naturally occurring autoantibodies against β-Amyloid
Abstract
Naturally occurring antibodies (NAbs) have been described for more than 30 years. Recently, NAbs against β-Amyloid and against other proteins involved in neurodegenerative disorders have been detected in humans. Based on the current evidence, it is hypothesized that anti-Aβ NAbs can inhibit the fibrillation and toxicity of β-aymloid, can improve cognition in a transgenic mouse model and interfere with oligomers of Aβ. Different functions of these NAbs have been described in the current literature. Based on the results of the diverse studies a Phase-III study using IVIG has been initiated in patients with AD. The results will show whether the application of NAbs will change the fate of the disease. This chapter summarizes our current knowledge on NAbs against Aβ.
Similar articles
-
Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin.Neuropharmacology. 2016 Jun;105:561-576. doi: 10.1016/j.neuropharm.2016.02.015. Epub 2016 Feb 18. Neuropharmacology. 2016. PMID: 26907803
-
Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease.J Neurosci. 2011 Apr 13;31(15):5847-54. doi: 10.1523/JNEUROSCI.4401-10.2011. J Neurosci. 2011. PMID: 21490226 Free PMC article.
-
Effect of Different Aβ Aggregates as Antigen on the Measure of Naturally Occurring Autoantibodies against Amyloid-β40/42 in IVIG.Curr Alzheimer Res. 2019;16(14):1290-1299. doi: 10.2174/1567205017666200102151731. Curr Alzheimer Res. 2019. PMID: 31894747
-
Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.Drugs. 2010 Mar 26;70(5):513-28. doi: 10.2165/11533070-000000000-00000. Drugs. 2010. PMID: 20329802 Review.
-
Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.J Clin Immunol. 2010 May;30 Suppl 1(Suppl 1):S43-9. doi: 10.1007/s10875-010-9414-5. J Clin Immunol. 2010. PMID: 20454852 Free PMC article. Review.
Cited by
-
A lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brain.J Biol Chem. 2013 May 24;288(21):15154-66. doi: 10.1074/jbc.M112.439570. Epub 2013 Apr 11. J Biol Chem. 2013. PMID: 23580652 Free PMC article.
-
Comparison of cerebrospinal fluid profiles in Alzheimer's disease with multiple cerebral microbleeds and cerebral amyloid angiopathy-related inflammation.J Neurol. 2017 Feb;264(2):373-381. doi: 10.1007/s00415-016-8362-2. Epub 2016 Dec 20. J Neurol. 2017. PMID: 28000005
-
Serum Inflammatory Profile in Hereditary Transthyretin Amyloidosis: Mechanisms and Possible Therapeutic Implications.Brain Sci. 2022 Dec 12;12(12):1708. doi: 10.3390/brainsci12121708. Brain Sci. 2022. PMID: 36552168 Free PMC article.
-
Peripheral Routes to Neurodegeneration: Passing Through the Blood-Brain Barrier.Front Aging Neurosci. 2020 Feb 4;12:3. doi: 10.3389/fnagi.2020.00003. eCollection 2020. Front Aging Neurosci. 2020. PMID: 32116645 Free PMC article. Review.
-
Body fluid biomarkers in Alzheimer's disease.Ann Transl Med. 2015 Apr;3(5):70. doi: 10.3978/j.issn.2305-5839.2015.02.13. Ann Transl Med. 2015. PMID: 25992369 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
